Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
| Grant Information: | R01 DE12581 United States DE NIDCR NIH HHS |
|---|---|
| Substance Nomenclature: | 0 (DNA-Binding Proteins) 0 (Intracellular Signaling Peptides and Proteins) 0 (Isoenzymes) 0 (Receptors, Fibroblast Growth Factor) 0 (STAT1 Transcription Factor) 0 (STAT1 protein, human) 0 (STAT3 Transcription Factor) 0 (STAT3 protein, human) 0 (Stat1 protein, mouse) 0 (Stat1 protein, rat) 0 (Stat3 protein, mouse) 0 (Stat3 protein, rat) 0 (Trans-Activators) 0I3V7S25AW (Myristic Acid) EC 2.7.1.- (Phosphatidylinositol 3-Kinases) EC 2.7.10.1 (FGFR1 protein, human) EC 2.7.10.1 (FGFR3 protein, human) EC 2.7.10.1 (FGFR4 protein, human) EC 2.7.10.1 (Fgfr1 protein, mouse) EC 2.7.10.1 (Fgfr1 protein, rat) EC 2.7.10.1 (Fgfr3 protein, mouse) EC 2.7.10.1 (Fgfr4 protein, mouse) EC 2.7.10.1 (Fgfr4 protein, rat) EC 2.7.10.1 (Protein-Tyrosine Kinases) EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1) EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 4) EC 2.7.11.24 (Mitogen-Activated Protein Kinases) EC 3.1.3.48 (PTPN11 protein, human) EC 3.1.3.48 (PTPN6 protein, human) EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 1) EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11) EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 6) EC 3.1.3.48 (Protein Tyrosine Phosphatases) EC 3.1.3.48 (Ptpn11 protein, mouse) EC 3.1.3.48 (Ptpn11 protein, rat) EC 3.1.3.48 (Ptpn6 protein, mouse) EC 3.1.3.48 (Ptpn6 protein, rat) EC 3.1.4.- (Type C Phospholipases) EC 3.1.4.3 (Phospholipase C gamma) |
| Entry Date(s): | Date Created: 20000805 Date Completed: 20000816 Latest Revision: 20220318 |
| Update Code: | 20221213 |
| DOI: | 10.1038/sj.onc.1203650 |
| PMID: | 10918587 |
| Autor: | Hart KC; Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla 92093-0367, USA., Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ |
| Jazyk: | angličtina |
| Zdroj: | Oncogene [Oncogene] 2000 Jul 06; Vol. 19 (29), pp. 3309-20. |
| DOI: | 10.1038/sj.onc.1203650 |
| Abstrakt: | The fibroblast growth factor receptor (FGFR) family members mediate a number of important cellular processes, and are mutated or overexpressed in several forms of human cancer. Mutation of Lys650-->Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas. This mutation leads to constitutive activation of FGFR3. To compare the signaling activity of FGFR family members, this activating mutation was generated in FGFR1, FGFR3, and FGFR4. We show that the kinase domains of FGFR1, FGFR3, and FGFR4 containing the activation loop mutation, when targeted to the plasma membrane by a myristylation signal, can transform NIH3T3 cells and induce neurite outgrowth in PC12 cells. Phosphorylation of Shp2, PLC-gamma, and MAPK was also stimulated by all three 'TDII-like' FGFR derivatives. Additionally, activation of Stat1 and Stat3 was observed in cells expressing the activated FGFR derivatives. Finally, we demonstrate that FGFR1, FGFR3, and FGFR4 derivatives can stimulate PI-3 kinase activity. Our comparison of these activated receptor derivatives reveals a significant overlap in the panel of effector proteins used to mediate downstream signals. This also represents the first demonstration that activation of FGFR4, in addition to FGFR1 and FGFR3, can induce cellular transformation. Moreover, our results suggest that Stat activation by FGFRs is important in their ability to act as oncogenes. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|